The two studies were presented during Association for Molecular Pathology 2017 Annual Meeting from November 16 - 18, 2017 in Salt Lake City, Utah.
· Two medical institutions present first HDPCR™ data during AMP 2017 Annual Meeting.
|
| [21-November-2017] |
| CARLSBAD, Calif., Nov. 21, 2017 /PRNewswire/ -- ChromaCode, a molecular diagnostic company enabling labs to enhance multiplexing capabilities on existing life science instrumentation, today announced the publication of studies from Dartmouth-Hitchcock Medical Center and Keck Medicine of USC highlighting the utility of the company’s HDPCR™ chemistry and the performance of the HDPCR respiratory assay (IUO). The two studies were presented during Association for Molecular Pathology (AMP) 2017 Annual Meeting from November 16 - 18, 2017 in Salt Lake City, Utah.
The Dartmouth data tested HDPCR’s ability to expand the multiplexing capability of traditional real-time PCR instruments. “We were impressed with the HDPCR’s ability to increase the multiplexing capabilities of our existing equipment without any modifications to the instrument or software. With the ongoing pressure to provide more comprehensive diagnostics at a lower cost, HDPCR promises to address this need and provides the versatility for use in infectious disease, oncology and genetic applications,” said Greg Tsongalis, PhD, HCLD, CCC, Director, Laboratory for Clinical Genomics and Advanced Technology, Dartmouth-Hitchcock Medical Center. The USC study evaluated the performance of the HDPCR respiratory assay (IUO) for the detection of common respiratory pathogens from nasopharyngeal swab specimens. The study noted high concordance between HDPCR and a commercially available respiratory pathogen panel. “Our technicians really liked the workflow and how similar it was to traditional real-time PCR. The user interface and platform are particularly well-suited to high-volume laboratories,” said Pamela Ward, PhD, associate professor of clinical pathology at the Keck School of Medicine of USC. About ChromaCode Based in Carlsbad, Calif., ChromaCode is a molecular diagnostics company with a bioinformatics focus and pedigree from Illumina, Google[X], Luminex, and Caltech. By leveraging patented mathematical methods and algorithmic enhancements, the company’s HDPCR™ technology enriches signal processing for the most popular life science instrumentation. In doing this, HDPCR enables laboratorians to extract new information on biochemistry reactions and substantially increase the performance and multiplexing capabilities of today’s gold-standard biochemical assays in a highly cost-effective manner.
View original content:http://www.prnewswire.com/news-releases/dartmouth-and-university-of-southern-california-studies-highlight-chromacode-hdpcr-as-compelling-multiplexing-alternative-300559533.html SOURCE ChromaCode, Inc. |
